| NCT07173751 | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | NOT_YET_RECRUITING | PHASE3 | 2025-10 | 2030-09 | 2029-12 |
| NCT07186842 | A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 | NOT_YET_RECRUITING | PHASE1, PHASE2 | 2025-10 | 2030-05 | 2030-05 |
| NCT07111520 | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) | NOT_YET_RECRUITING | PHASE1, PHASE2 | 2025-09 | 2030-01 | 2029-01 |
| NCT07147348 | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2025-08-27 | 2028-03 | 2027-12 |
| NCT07070232 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | RECRUITING | PHASE1, PHASE2 | 2025-08-12 | 2030-02 | 2028-05 |
| NCT07079631 | A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer | RECRUITING | PHASE1, PHASE2 | 2025-07-18 | 2031-05 | 2030-12 |
| NCT07069309 | A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Adults, Including Those at Higher Risk of Severe COVID-19 | RECRUITING | PHASE3 | 2025-07-08 | 2026-01-06 | 2026-01-06 |
| NCT06940804 | A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm | WITHDRAWN | PHASE2 | 2025-07 | 2042-06 | 2042-06 |
| NCT06340568 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer | RECRUITING | PHASE3 | 2025-06-10 | 2029-11 | 2028-03 |
| NCT06892548 | A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer | RECRUITING | PHASE1, PHASE2 | 2025-05-02 | 2031-06 | 2027-08 |
| NCT06827236 | A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer | RECRUITING | PHASE1, PHASE2 | 2025-04-23 | 2029-05 | 2028-05 |
| NCT06841055 | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy Following Chemoimmunotherapy | RECRUITING | PHASE2 | 2025-03-03 | 2028-10 | 2028-10 |
| NCT06821061 | A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People | RECRUITING | PHASE1, PHASE2 | 2025-02-10 | 2025-12-22 | 2025-12-22 |
| NCT06712355 | Safety and Effectiveness of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE3 | 2025-02-03 | 2028-09 | 2028-04 |
| NCT06750185 | Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors | RECRUITING | PHASE1 | 2025-01-13 | 2028-06 | 2028-06 |
| NCT06712316 | Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | RECRUITING | PHASE2, PHASE3 | 2025-01-07 | 2030-12 | 2029-12 |
| NCT05630352 | A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children | WITHDRAWN | PHASE1 | 2025-01-06 | 2026-07-13 | 2026-07-13 |
| NCT06683352 | A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People | COMPLETED | PHASE1, PHASE2 | 2024-11-11 | 2025-07-15 | 2025-07-15 |
| NCT06449222 | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy | RECRUITING | PHASE2 | 2024-08-26 | 2029-06 | 2028-08 |
| NCT06449209 | Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-08-05 | 2028-05 | 2027-06 |
| NCT06469164 | A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis | COMPLETED | PHASE1 | 2024-07-01 | 2025-07-31 | 2025-07-31 |
| NCT06069778 | Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma | TERMINATED | PHASE1, PHASE2 | 2024-03-27 | 2024-09-18 | 2024-09-18 |
| NCT06178991 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. | COMPLETED | PHASE3 | 2023-12-20 | 2024-11-26 | 2024-11-26 |
| NCT06150183 | Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors | RECRUITING | PHASE1 | 2023-11-30 | 2026-09 | 2026-09 |
| NCT06069544 | A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-11-13 | 2026-03 | 2025-05-28 |
| NCT05988203 | A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-09-21 | 2026-03 | 2025-09 |
| NCT05997290 | A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals | COMPLETED | PHASE2, PHASE3 | 2023-08-10 | 2025-03-13 | 2025-03-13 |
| NCT05547464 | Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers | RECRUITING | PHASE1, PHASE2 | 2023-07-31 | 2027-05 | 2026-06 |
| NCT05537038 | Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-04-18 | 2025-12 | 2025-06-06 |
| NCT05581641 | Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria | COMPLETED | PHASE1 | 2022-12-15 | 2024-09-06 | 2024-02-23 |
| NCT05432583 | A Clinical Trial in Healthy Volunteers and Volunteers with Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination with an Investigational Vaccine Designed to Prevent Genital Herpes Lesions | RECRUITING | PHASE1 | 2022-12-08 | 2026-10 | 2026-10 |
| NCT05541861 | Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People | COMPLETED | PHASE1 | 2022-11-08 | 2024-11-22 | 2024-11-22 |
| NCT05596734 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza | COMPLETED | PHASE2 | 2022-10-28 | 2023-12-28 | 2023-12-28 |
| NCT05543616 | A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children | RECRUITING | PHASE2, PHASE3 | 2022-09-23 | 2026-06-16 | 2026-06-16 |
| NCT05472038 | A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals | COMPLETED | PHASE2, PHASE3 | 2022-07-26 | 2024-03-26 | 2024-03-26 |
| NCT05142189 | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | RECRUITING | PHASE1 | 2022-06-17 | 2031-11 | 2030-02 |
| NCT05310084 | Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age | COMPLETED | PHASE3 | 2022-04-20 | 2022-10-05 | 2022-10-05 |
| NCT05262530 | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-03-28 | 2025-12 | 2025-12 |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | TERMINATED | PHASE1, PHASE2 | 2022-01-18 | 2023-07-24 | 2023-07-24 |
| NCT04895982 | Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years | COMPLETED | PHASE2 | 2021-10-15 | 2023-07-23 | 2023-07-23 |
| NCT05004181 | Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants | COMPLETED | PHASE2 | 2021-08-25 | 2023-10-04 | 2023-08-16 |
| NCT04949490 | A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects | COMPLETED | PHASE2 | 2021-07-26 | 2022-09-16 | 2022-04-14 |
| NCT04955626 | To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. | COMPLETED | PHASE3 | 2021-07-01 | 2023-05-25 | 2023-05-25 |
| NCT04710043 | Dose Escalation Trial of BNT152+153 in Patients With Cancer | COMPLETED | PHASE1 | 2021-06-08 | 2025-09-10 | 2025-09-10 |
| NCT04526899 | A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-05-19 | 2025-12 | 2024-01-25 |
| NCT04816669 | A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults | COMPLETED | PHASE3 | 2021-04-01 | 2021-12-02 | 2021-12-01 |
| NCT04816643 | A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children | COMPLETED | PHASE2, PHASE3 | 2021-03-24 | 2023-12-08 | 2023-10-04 |
| NCT04486378 | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | RECRUITING | PHASE2 | 2021-03-08 | 2030-08 | 2026-11 |
| NCT04754594 | To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older | COMPLETED | PHASE2, PHASE3 | 2021-02-16 | 2022-07-15 | 2022-07-15 |
| NCT04713553 | A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants | COMPLETED | PHASE3 | 2021-02-15 | 2021-07-22 | 2021-07-22 |
| NCT04455620 | BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2021-01-26 | 2024-05-28 | 2024-05-28 |
| NCT04534205 | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | RECRUITING | PHASE2, PHASE3 | 2021-01-07 | 2029-04 | 2029-04 |
| NCT04649021 | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population | COMPLETED | PHASE2 | 2020-12-04 | 2022-01-09 | 2021-02-07 |
| NCT04625205 | A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma | TERMINATED | PHASE1 | 2020-12-01 | 2025-03-26 | 2025-03-26 |
| NCT04588480 | Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults | COMPLETED | PHASE4 | 2020-10-21 | 2021-11-25 | 2021-11-25 |
| NCT04503278 | A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors | RECRUITING | PHASE1 | 2020-09-16 | 2041-01 | 2028-01 |
| NCT04537949 | A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults | COMPLETED | PHASE1, PHASE2 | 2020-09-09 | 2022-02-07 | 2021-03-12 |
| NCT04523571 | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects | COMPLETED | PHASE1 | 2020-07-28 | 2021-08-10 | 2020-09-30 |
| NCT04101357 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | TERMINATED | PHASE1, PHASE2 | 2020-06-19 | 2024-05-23 | 2024-01-19 |
| NCT04368728 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | COMPLETED | PHASE2, PHASE3 | 2020-04-29 | 2023-02-10 | 2023-02-10 |
| NCT04380701 | A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults | COMPLETED | PHASE1, PHASE2 | 2020-04-23 | 2022-04-13 | 2021-06-30 |
| NCT04382898 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) | TERMINATED | PHASE1, PHASE2 | 2019-12-19 | 2024-01-23 | 2024-01-23 |
| NCT03597282 | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | TERMINATED | PHASE1 | 2018-10-08 | 2020-08-11 | 2020-05-05 |
| NCT03380871 | A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | COMPLETED | PHASE1 | 2018-05-04 | 2021-02-05 | 2019-10-31 |
| NCT03118349 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy | TERMINATED | PHASE1 | 2017-06-01 | 2018-04-11 | 2018-04-11 |
| NCT02316457 | RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID | COMPLETED | PHASE1 | 2016-10 | 2023-05-17 | 2020-05-13 |
| NCT02897765 | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | COMPLETED | PHASE1 | 2016-10 | 2020-05 | 2019-02 |
| NCT02687230 | Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1 | TERMINATED | PHASE1 | 2016-07-11 | 2017-05-05 | 2017-05-05 |
| NCT02672917 | Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies | TERMINATED | PHASE1 | 2016-01 | 2025-01-14 | 2024-08-07 |
| NCT02410733 | Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma | COMPLETED | PHASE1 | 2015-03 | 2023-06-20 | 2023-06-20 |
| NCT02035956 | IVAC MUTANOME Phase I Clinical Trial | COMPLETED | PHASE1 | 2013-12 | 2019-10 | 2017-02-14 |
| NCT01684241 | RBL001/RBL002 Phase I Clinical Trial | COMPLETED | PHASE1 | 2012-06 | 2015-07 | 2015-05 |